TLR4 and melanoma: Other TLR4 antagonists, including eritoran, (+)-naloxone, ST2825, and resatorvid, should have also shown beneficial effects in skin cancers, including melanoma (Blohm-Mangone et al., 2018[10]; Dickinson and Wondrak, 2018[37]; Janda et al., 2016[77]).